Xvivo Perfusion (Q3 Initial take): Strong sales growth, boosted by Thoracic - Redeye

Redeye shares its initial take on XVIVO’s Q3 2026 report. Sales exceeded both our estimates and consensus, driven by strong Thoracic sales, although the segment benefited from some positive timing effects. Profitability also came in ahead of expectations, despite a weaker gross margin. We expect a positive share price reaction of 5–7% today.

Länk till analysen i sin helhet: https://www.redeye.se/research/1188239/xvivo-perfusion-q3-initial-take-strong-sales-growth-boosted-by-thoracic?utm_source=finwire&utm_medium=RSS